Our Myeloma 200 Challenge has come to an end. Congratulations to Yelena Kotlyar on winning the grand prize – a trip for 2 to Costa Rica!! Thanks to our 24 participants and the 125 people who helped raise nearly $25K for myeloma research, education, support and advocacy! READ MORE
World Experts Debate the Latest Advances in Myeloma Treatment
Members of the International Myeloma Working Group kick off the inaugural IMWG Conference Series. Drs. Durie, San Miguel, Richardson, and Palumbo will debate topics of crucial concern including: frontline therapies, the current role of maintenance and new drugs. This event will take place on June 13th - 1:00PM (Central European Summer Time) at the Sofitel Legend Hotel, Amsterdam, and will be live-streamed for global viewing. This conference will be archived for viewing on the IMF’s website myeloma.org. Click HERE to register to attend the Conference in Amsterdam. Click HERE to register for the live-streaming.
Oral Drugs vs. Outdated Policies: IMF Advocacy in the News
"Multiple myeloma is a relapsing-and-remitting disease,” the IMF’s Arin Assero tells The Washington Post. “At some point patients are going to have to access” all types of treatment. That includes new oral cancer drugs. Insurers say they don’t want to be dictated to, but studies show oral oncology parity laws don’t necessarily drive up costs. READ MORE
Guiding the Nurses Who Guide the Patients
When more than 600 oncology nurses from across the country gathered in New Orleans this month for the Oncology Nursing Society’s 37th Annual Congress they saw a presentation of the visionary “Survivorship Plans” created by the IMF Nurse Leadership Board. With novel therapies, patients are living longer. These plans are designed to help patients optimize their health and improve their quality of life. READ MORE
Riding Tandem Through Life: Myeloma Caregiver Wife Blog
“Caregivers become hyper vigilant, and it is assumed that patients will always be grateful for the help and love they receive. But it isn't simple for any of us. Often we become so accustomed to our roles that we can't re-adjust when it's time to resume ‘normal’ life.” READ MORE
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care® 10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique
New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage
Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre
Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific
ABOUT BSRI™
ABOUT BSRI™
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
IMF 6th Annual Comedy Celebration benefiting the Peter Boyle Research Fund October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
November 8, 2012
Myeloma Minute
October 25, 2012
Myeloma Minute June 13, 2013
Myeloma Minute May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie September 8,2011
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
Клиническое значение электрофореза белковых фракций
back
Our Myeloma 200 Challenge has come to an end. Congratulations to Yelena Kotlyar on winning the grand prize – a trip for 2 to Costa Rica!! Thanks to our 24 participants and the 125 people who helped raise nearly $25K for myeloma research, education, support and advocacy! 
print
related videos
related articles
